Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 6/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | OXTR | P30559 | 2/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5493470 | 0.83 | EGLN2 (0.45) | EGLN2KCNH2GRM5KDM4EALDH1A1 | |
| SCHEMBL13185348 | 0.82 | KDM4E (0.44) | EGLN2KCNH2GRM5KDM4EALDH1A1 | |
| SCHEMBL5487740 | 0.76 | GRM5 (0.45) | EGLN2KCNH2CYP11B2CYP11B1GRM5 | |
| SCHEMBL4187933 | 0.76 | GRM5 (0.49) | EGLN2KCNH2CYP11B1GRM5 | |
| SCHEMBL3505152 | 0.75 | GRM5 (0.41) | EGLN2KCNH2GRM5KDM4EALDH1A1 | |
| SCHEMBL3503836 | 0.74 | KDM4E (0.39) | EGLN2KCNH2GRM5KDM4EALDH1A1 | |
| SCHEMBL14046725 | 0.74 | KDM4E (0.39) | EGLN2KCNH2GRM5KDM4EALDH1A1 | |
| SCHEMBL5487833 | 0.73 | GRM5 (0.40) | EGLN2KCNH2GRM5KDM4EALDH1A1 | |
| SCHEMBL14046723 | 0.73 | EGLN2 (0.40) | EGLN2KCNH2GRM5KDM4EALDH1A1 | |
| SCHEMBL17630069 | 0.72 | CYP11B2 (0.44) | EGLN2KCNH2CYP11B2CYP11B1OXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7256203-B2 | Dicationic 2,5-diarylfuran aza-analogs as anti-protozoan agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2007-08-14 | — | — | US | disclosed |
| US-7256203-B2 | Dicationic 2,5-diarylfuran aza-analogs as anti-protozoan agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2007-08-14 | — | — | US | disclosed |
| EP-1565458-A2 | DICATIONIC 2,5-DIARYLFURAN AZA-ANALOGS AS ANTI-PROTOZOAN AGENTS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2005-08-24 | — | — | EP | disclosed |
| US-20040122015-A1 | Dicationic 2,5-diarylfuran aza-analogs as anti-protozoan agents | BOYKIN DAVID W (US) | 2004-06-24 | — | — | US | disclosed |
| WO-2004050018-A2 | DICATIONIC 2,5-DIARYLFURAN AZA-ANALOGS AS ANTI-PROTOZOAN AGENTS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122015-A1 | Dicationic 2,5-diarylfuran aza-analogs as anti-protozoan agents | NR0B1, NR2C2, DECR1 | EGLN2 1489/4885KCNH2 1516/4885CYP11B2 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.